Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Annovis Bio, Inc. ANVS NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$25.67
+1383.8%

Annovis Bio, Inc. (ANVS) is a Biotechnology company in the Healthcare sector, currently trading at $1.73. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ANVS = $26 (+1383.8% upside).

Valuation: ANVS trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.25.

Net income is $29M (loss), growing at -14558%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $17M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.8 (strong liquidity). Debt-to-assets is 0%. Total assets: $21M.

Analyst outlook: 6 / 8 analysts rate ANVS as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).

$25.67
▲ 1383.82% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Annovis Bio, Inc., the average price target is $25.67, with a high forecast of $30.00, and a low forecast of $21.00.
Highest Price Target
$30.00
Average Price Target
$25.67
Lowest Price Target
$21.00

ANVS SharesGrow Score Overview

66/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ANVS

✓
VALUE Pass
100/100
ANVS trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25). Forward PEG 0.25 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $26, implying +1402.9% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ANVS: +0%/yr revenue is, -14558%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ANVS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.8 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ANVS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 6 / 8 analysts rate ANVS as buy (75%). Analyst consensus target is $26 (+1402.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.11-5.5
Volume1.71M
Avg Volume (30D)620.09K
Market Cap$34.04M
Beta (1Y)1.36
Share Statistics
EPS (TTM)-1.40
Shares Outstanding$20.55M
IPO Date2020-01-29
Employees8
CEOCheng Fang
Financial Highlights & Ratios
EBITDA$-29.7M
Net Income$-28.85M
Operating Income$-29.7M
Total Cash$19.53B
Net Debt$-19.53B
Total Assets$21.08M
Price / Earnings (P/E)-1.2
Analyst Forecast
1Y Price Target$26.00
Target High$30.00
Target Low$21.00
Upside+1,402.9%
Rating ConsensusBuy
Analysts Covering8
Buy 75% Hold 25% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS03615A1088

Price Chart

Track all markets on TradingView
ANVS
Annovis Bio, Inc. ↗  ·  NYSE
Healthcare • Biotechnology
1.11 52WK RANGE 5.50

People Also View

AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+3.28%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 IMNM
IMNM
Immunome, Inc.
$22.90
+1.24%
 NVAX
NVAX
Novavax, Inc.
$8.39
+3.45%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 AVXL
AVXL
Anavex Life Sciences Corp.
$3.12
+0.32%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message